AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
-1.45%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$635M
AUM Growth
+$635M
(+3.2%)
Cap. Flow
+$13M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
39.19%
Holding
115
New
23
Increased
29
Reduced
18
Closed
15
Top Buys
| 1 |
Alkermes
ALKS
|
$13.9M |
| 2 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$11.9M |
| 3 |
Apogee Therapeutics
APGE
|
$9.61M |
| 4 |
Arcellx
ACLX
|
$8.83M |
| 5 |
Insmed
INSM
|
$8.38M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$9.7M |
| 2 |
Absci
ABSI
|
$5.82M |
| 3 |
Cytokinetics
CYTK
|
$5.61M |
| 4 |
Fulcrum Therapeutics
FULC
|
$5.2M |
| 5 |
Axsome Therapeutics
AXSM
|
$4.81M |
Sector Composition
| 1 | Healthcare | 89.38% |
| 2 | Financials | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Insmed
INSM
$30.3B
| $8.38M | 0.97% |
+125,000
| New | +$8.38M |
|
27
NewAmsterdam Pharma
NAMS
$2.8B
| $8.13M | 0.94% |
423,155
+136,955
| +48% | +$2.63M |
|
28
Rezolute
RZLT
$630M
| $7.96M | 0.92% |
1,850,000
+250,000
| +16% | +$1.08M |
|
29
Merus
MRUS
$5.04B
| $7.4M | 0.85% |
+125,000
| New | +$7.4M |
|
|
30
Axsome Therapeutics
AXSM
$6.09B
| $6.44M | 0.74% |
80,000
-59,758
| -43% | -$4.81M |
|
31
Geron
GERN
$893M
| $6.36M | 0.73% |
1,500,000
-1,000,000
| -40% | -$4.24M |
|
32
Savara
SVRA
$591M
| $6.23M | 0.72% |
1,546,850
+396,850
| +35% | +$1.6M |
|
33
Erasca
ERAS
$406M
| $5.9M | 0.68% |
+2,499,431
| New | +$5.9M |
|
34
Perspective Therapeutics
CATX
$251M
| $5.48M | 0.63% |
550,000
+40,000
| +8% | +$399K |
|
35
Mirum Pharmaceuticals
MIRM
$3.75B
| $5.3M | 0.61% |
155,000
-5,000
| -3% | -$171K |
|
36
Cullinan Oncology
CGEM
$456M
| $4.6M | 0.53% |
263,817
+5,229
| +2% | +$91.2K |
|
37
Vaxcyte
PCVX
$4.17B
| $4.53M | 0.52% |
60,000
-20,000
| -25% | -$1.51M |
|
|
ELEV
38
DELISTED
Elevation Oncology
ELEV
| $3.97M | 0.46% |
1,468,825
+200,000
| +16% | +$540K |
|
39
HilleVax
HLVX
$105M
| $3.84M | 0.44% |
+265,859
| New | +$3.84M |
|
40
Mineralys Therapeutics
MLYS
$1.94B
| $3.84M | 0.44% |
327,959
| – | – |
|
41
Roivant Sciences
ROIV
$8.6B
| $3.72M | 0.43% |
351,587
-148,413
| -30% | -$1.57M |
|
42
Dyne Therapeutics
DYN
$1.92B
| $3.53M | 0.41% |
+100,000
| New | +$3.53M |
|
|
PCSC
43
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $3.52M | 0.41% |
+350,000
| New | +$3.52M |
|
44
Immatics
IMTX
$662M
| $3.49M | 0.4% |
300,000
-50,000
| -14% | -$581K |
|
45
SPDR S&P Biotech ETF
XBI
$5.29B
| $3.48M | 0.4% |
+37,550
| New | +$3.48M |
|
46
Context Therapeutics
CNTX
$75.6M
| $3.25M | 0.37% |
1,619,140
+1,290,323
| +392% | +$2.59M |
|
47
Black Diamond Therapeutics
BDTX
$164M
| $3.03M | 0.35% |
+650,000
| New | +$3.03M |
|
|
CMPS
48
Compass Pathways
CMPS
$452M
| $3.02M | 0.35% |
500,512
-527,356
| -51% | -$3.19M |
|
49
Olema Pharmaceuticals
OLMA
$432M
| $2.98M | 0.34% |
+275,000
| New | +$2.98M |
|
50
NextCure
NXTC
$13.3M
| $2.68M | 0.31% |
140,663
+27,410
| +24% | +$523K |
|